Enoda

Enoda is a synthetic biology and cell therapy company developing a novel platform of synthetic cytokine receptors called MIMICs (Modular Immune-Mediated Intracellular Constructs) that engineer any cell type into a therapeutic cure. Co-founded in 2023 by Michael Chavez (CEO) and Paul Finn (CTO), the company's technology solves a core protein engineering challenge by linking Signal 3 cytokine signaling to clinically relevant inputs without systemic toxicity, expanding what engineered cells can do. Enoda's platform is designed for partnering with CAR T cell, regulatory T cell, macrophage, and stem cell therapy programs to expand the scope of durable cell therapy cures.